Compare Kraft Heinz Co (KHC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Organon & Co. Common Stock — how do they compare? Kraft Heinz Co trades at $22.91 (market cap $26.60B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Kraft Heinz Co is far larger — about 7.3× Organon & Co. Common Stock's market cap, and Kraft Heinz Co pays the higher dividend (7.13%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Organon & Co. Common Stock for 0 Days on average.
| KHC | OGN | |
|---|---|---|
Market Cap | $26.60B | $3.62B |
Volume | 11,136,448 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $13.81 |
52-Week Low | $21.21 | $5.70 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $42.92B | $11.04B |
Dividend Yield | 7.13% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.70, up 1.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals, including a negative net income margin of -13.64% for 2025 but a low P/B of 0.74, suggesting potential undervaluation. Recent news highlights the company's $700 million reinvestment plan and new product launches like Philadelphia cream cheese flavors to revive brands amid volume challenges.
The outlook remains cautious due to persistent profitability issues and high debt, though the dividend yield near 6.5% and analyst consensus price target of $24.11 offer some upside. Key risks include execution of the turnaround strategy and competitive pressures in the consumer goods sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
